In general, only unbound drug can traverse biological membranes and produce a pharmacological effect and, therefore, the therapeutic activities of drugs usually correlate with the concentration of unbound drug in blood. 10, 11) Thus, high affinity binding to hAGP may prevent UCN-01 being delivered to the cytoplasm of the tumor and interacting with the target molecules, PKC and CDK2. When the plasma molar concentrations of UCN-01 are less than those of hAGP, all the administered UCN-01 would be present in the hAGPbound form. 6, 8) Free UCN-01 would appear in blood only when the plasma molar concentrations of UCN-01 are above the hAGP levels. Consequently, administration of high doses of UCN-01 to patients would be required to provide free UCN-01 in plasma and to exhibit antitumor activity. However, high doses of UCN-01 must be administered with caution because interpatient variation in AGP levels is relatively large; therefore, some patients are likely to exhibit rapid increases in the concentration of free UCN-01 in blood and consequently be at risk from severe side effects. Additionally, the problem of inconsistent levels of AGP may be compounded by the possibility of intrapatient variation that can occur in several disease states, including cancer, depression, rheumatoid arthritis and severe burns. 10, 12) Therefore, in order to avoid side effects, hAGP should be measured in each patient prior to administration of high doses of UCN-01 and the concentration of free UCN-01 should be monitored after administration of the drug. It may also be necessary to administer the drug using a dose escalation protocol to ensure that the total plasma concentration of UCN-01 is comparable or exceeds hAGP levels in each patient thereby providing concentrations of free drug in plasma that can produce therapeutic benefit but are not sufficiently high to cause side effects. Thus, although UCN-01 is a promising drug, the high affinity binding to hAGP may compromise straightforward therapeutic application of the drug to provide safe and effective treatment. Therefore, we considered approaches that might negate the effect of high affinity binding of UCN-01 to hAGP.
Encapsulation of UCN-01 in liposomes was proposed as a possible method of avoiding the therapeutic impact of the high affinity binding of UCN-01 to hAGP. Liposomes, especially polyethylene glycol (PEG) liposomes, are widely used as carriers for many anticancer drugs such as doxorubicin 13, 14) and cisplatin. 15) In general, encapsulation into PEG liposomes increases the efficacy and decreases the side effects of anticancer drugs because the drugs are delivered preferentially to tumor tissue due to the enhanced permeability and retention effect. 16, 17) In addition, encapsulation in liposomes can prevent drugs interacting directly with blood components; for example, topotecan and antisense oligonucleotides are unstable in blood but degradation is reduced when they are encapsulated in liposomes. 18, 19) Thus, after injection of PEG liposomes encapsulating UCN-01, the liposomes would be expected to accumulate in tumors and gradually release UCN-01; the local levels of UCN-01 would be higher than those of hAGP so that it may be possible to deliver therapeutically effective concentrations of UCN-01 to the cytoplasm of the tumor.
In this study, we adopted methods to incorporate UCN-01 in liposomes and we investigated the processes involved in the release of drug by monitoring the concentration of UCN-01 in different fractions after adding liposomal formulations of the drug to various media in the presence and absence of protein. We also measured blood levels of hAGP bound drug and drug retained in liposomes after intravenous administration to rats of mixtures of UCN-01 solution or UCN-01 liposomes and hAGP in order to gauge the feasibility of using liposomal preparations of UCN-01 to deliver therapeutic doses of the drug safely and effectively.
MATERIALS AND METHODS
Materials UCN-01 was produced by a fermentation technique in our laboratories as described previously.
1) Hydrogenated soy phosphatidylcholine (HSPC) was purchased from Nippon oil and fat (Tokyo, Japan). Methoxy-polyethyleneglycol (Mw 2000)-distearoylphosphatidylethanolamine (PEG-DSPE) was purchased from Avanti Polar Lipids (Alabaster, AL, U.S.A.). Sepharose CL-6B was purchased from Amersham-Pharmacia Biotech (Uppsala, Sweden). hAGP and rat AGP were purchased from Sigma Chemical (St. Louis, MO, U.S.A.). All other chemicals and solvents were of analytical grade.
Animals Male SD strain rats, 7 to 8 weeks of age (Nihon SLC, Hamamatsu, Japan, 240 to 300 g at the start of the experiments), were housed for about one week under controlled conditions with free access to food and water before use. The Welfare Committee for Experimental Animals in our institute approved all the experiments performed in the study.
Preparation of UCN-01 Solution UCN-01 was dissolved at 1 mg/ml in citric acid · H 2 O (5.7 mM), Na 2 HPO 4 · 12H 2 O (15.6 mM). 7) The solution was kept on ice and protected from light until used.
Preparation of UCN-01 Liposomes HSPC liposomes were formed by hydrating the lipid with a 100 mM citric acid solution (pH 4.0). The resulting liposomes were extruded four and ten times through two stacked Nuclepore polycarbonate membrane filters with pore sizes of 0.4 and 0.1 mm, respectively, at 70°C. The liposomes were diluted with 100 mM citric acid solution (pH 4.0) to give a lipid concentration of approximately 62.5 mg/ml. UCN-01 was added to the liposome preparation to give a UCN-01-to-lipid weight ratio of 0.02. The efficiency of incorporating UCN-01 into liposomes was dependent on the drug-to-lipid ratio of the incubation mixture; doxorubicin entrapment characteristics were also influenced by the druglipid ratio. 20) Increasing the drug-to-lipid weight ratio above 0.025 resulted in a lower trapping efficiency of UCN-01 but at a ratio of 0.02 the drug was encapsulated efficiently into liposomes and this ratio was considered as optimal. The exterior pH of the liposomal vesicles was then titrated to approximately 8.0 with 1.0 M NaOH, thus creating a pH gradient (acidic inside) across the vesicles. Water was added to give a UCN-01 concentration of 1 mg/ml and then the mixture was heated at 70°C for 5 min to encapsulate UCN-01 into liposomes.
PEG-DSPE/ethanol solution was added to the liposomes to give a ratio of PEG-DSPE 6.7% (mol/mol) and ethanol 4% (v/v) and heated at 70°C for 2 min.
The resultant liposomes were diluted with four volumes of water and centrifuged in an ultracentrifuge (Optima TM XL-A, Beckman, Fullerton, CA, U.S.A.) for 1 h at 110000ϫg. The supernatant containing unencapsulated UCN-01 and excess citric acid was removed and the liposomal pellet was resuspended in 20 mM citric acid solution (pH 7) to provide a preparation containing 1 mg/ml UCN-01.
The concentrations of lipids were determined using the phosphorus assay (Wako, Tokyo, Japan). The mean size of the liposome vesicles was measured by dynamic light scattering (ELS-800, Otsuka electronics, Osaka, Japan).
Elution Profile UCN-01 in solution, the UCN-01 liposomal preparation, hAGP in solution, a mixture of UCN-01 and hAGP, and a mixture of UCN-01 liposomes and hAGP were applied separately onto a Sepharose CL-6B column (2.0ϫ20 cm) equilibrated with phosphate buffered saline (PBS, pH 7.4) at 25°C. The elution flow rate was approximately 2 ml/min. The concentration of UCN-01 in the eluent was measured by high-performance liquid chromatography (HPLC) as described previously 21) and protein concentrations were determined using a Bio-Rad Protein Assay kit (BioRad, Hercules, CA, U.S.A.).
Release of UCN-01 from Liposomes Aliquots of the UCN-01 liposomal preparation were diluted with (i) PBS, (ii) hAGP in PBS, (iii) rat AGP in PBS, (iv) rat plasma and (v) hAGP added to rat plasma. The concentration of UCN-01 in each mixture was 1 mg/ml and, when present, the concentration of AGP was 0.5 mg/ml (i.e. the approximate UCN-01 : AGP molar ratio was 1 : 6; Mw of UCN-01 and AGP are 482.5 and 42000, respectively). The mixtures were incubated at 37°C and aliquots were removed at different times for determination of liposomal and protein-bound UCN-01; liposomal UCN-01 was separated from hAGP-bound UCN-01 and free UCN-01 by Sepharose CL-6B gel chromatography.
In Vitro hAGP Binding Experiments UCN-01 solution (100 mg/ml) and UCN-01 liposomes (100 mg/ml UCN-01) were diluted with 99 volumes of rat plasma supplemented with hAGP and incubated at 37°C. The final concentrations of UCN-01 and hAGP in the mixtures were 1 mg/ml and 0.5 mg/ml, respectively. Aliquots were removed at different times for determination of hAGP-bound UCN-01. hAGPbound UCN-01 was separated from liposomal UCN-01 and free UCN-01 by Sepharose CL-6B gel chromatography.
Rat PK A solution of hAGP (92.6 mg/ml) was prepared in physiological saline. Aliquots of a solution of UCN-01 and a UCN-01 liposomal preparation were diluted with physiological saline to provide solutions containing 0.175 mg/ml UCN-01 as described previously. 7) Similarly, aliquots of a UCN-01 solution and UCN-01 liposomes were mixed with the hAGP solution to give mixtures containing 0.175 mg/ml UCN-01 and 76.5 mg/ml hAGP. A group of three was randomly selected from the population. The rats were fixed in a dorsal position under urethane anesthesia (1 g/kg, i.p.). Each of these four solutions was administered rapidly to rats via the tail vein at a volume of 2 ml/kg. The doses of UCN-01 and hAGP were 0.35 mg/kg and 153 mg/kg (0.725, 3.625 mmol/kg), respectively. For the analysis of the blood concentrations of UCN-01, approximately 0.3 ml blood was withdrawn from the jugular vein using heparinized syringes at 0.083, 1, 3, 6 and 24 h after dosing. The UCN-01 concentration in each blood sample was measured by HPLC 21) and the % of the injected dose present in the blood compartment was calculated assuming that the blood volume of a 250 g rat is 13.5 ml. 22) In Vivo hAGP Binding Experiments Each blood sample that was collected during the above rat PK studies was immediately applied to a column of Sepharose CL-6B, as described for the in vitro release experiments, to separate hAGP-bound UCN-01 from liposomal UCN-01 and free UCN-01. The concentration of UCN-01 in each fraction was measured by HPLC.
Data Analysis All data are presented as the meanϮS.D. of three animals or experiments. The pharmacokinetic parameters in rats were calculated from the individual blood concentration-time curves after intravenous injection by a noncompartment model using the pharmacokinetics software package WinNonlin TM Professional Ver. 4.0.1 (Pharsight Co., Mountain View, CA, U.S.A.). The areas under the blood concentration-time curves (AUC 0-∞ ) were calculated using the trapezoidal rule and by extrapolating the time to infinity using the elimination rate constant (k el ) values. The elimination half-life (t 1/2 ) was calculated as 0.693/k el . The total body clearance (CL tot ) was calculated from Dose/AUC 0-∞ . The mean residence time (MRT) was calculated as AUMC/AUC, (AUMC is the area under the first moment curve). The volume of distribution at steady-state (V dss ) was calculated as CL tot · MRT. Statistical significance was estimated by using the Student's t-test with equal variance recognized by the F test or the Aspin-Welch test with unequal variance by the F test. p value of less than 0.05 were considered statistically significant.
RESULTS

Preparation of UCN-01 Liposomes
A formulation of UCN-01 in liposomes was prepared successfully using the procedure described in Materials and Methods; the mean particle size of the liposomes was 112 nm.
Elution Profiles Liposomal UCN-01, hAGP-bound UCN-01 and free UCN-01 were separated by chromatography on Sepharose CL-6B (Figs. 2a, b) . No free drug was detected even when gel filtration was performed immediately after mixing solutions of UCN-01 and hAGP, all the UCN-01 was associated with the hAGP fraction (Fig. 2b) . Thus, in the presence of excess hAGP, UCN-01 binds quantitatively and rapidly to hAGP. Theoretically unbound drug would be present in an equilibrium condition. If the detection sensitivity of UCN-01 was high, unbound drug concentration would be able to be analyzed. However, alternative method using an ultracentrifugation also showed that unbound fraction in human plasma was less than the lower of detection (Ͻ0.02%) and substantially lower in comparison with other animals. 6) The amount of free UCN-01 in human plasma or rat plasma added hAGP is so small that we may say that the existence of free fraction is negligible. All the experiments reported below were conducted in the presence of excess hAGP.
The elution profiles of UCN-01 obtained 0 and 3 h after adding liposomes to hAGP enriched rat plasma revealed that UCN-01 in the liposomal fraction decreased over time with a corresponding increase of drug in the hAGP fraction (Fig.  2c) . Other proteins in rat plasma co-elute with hAGP, therefore, it is possible that some UCN-01 is bound to rat plasma proteins. However, because of the specific, high affinity binding of UCN-01 to hAGP, [6] [7] [8] most of the UCN-01 that is eluted in this fraction is probably bound to hAGP.
Release of UCN-01 from Liposomes Little release of UCN-01 from liposomes was observed over 24 h when the liposomes were placed in PBS with or without rat AGP (Fig.  3) . However, rapid release of UCN-01 from liposomes was observed when the liposomes were incubated with hAGP in PBS, and in rat plasma with and without the addition of hAGP (Fig. 3) . Thus, the release of UCN-01 from liposomes is influenced markedly by the presence of plasma components, particularly hAGP, that are capable of binding the drug. After 24 h incubation, the amount of UCN-01 released from liposomes added to hAGP enriched rat plasma, rat plasma alone and hAGP in PBS was 97.8%, 94.1% and 88.4%, respectively.
In Vitro hAGP Binding Experiments When a solution of UCN-01 was mixed with hAGP, all the UCN-01 bound to hAGP immediately and binding was maintained for at least 24 h (Fig. 4) . When UCN-01 liposomes were incubated with hAGP, the drug was gradually released from the liposomes and all the released UCN-01 bound to hAGP (Fig. 4) ; 12.3% of UCN-01 was retained in liposomes at 6 h and this proportion declined to 2.2% at 24 h. Thus, binding of UCN-01 to hAGP was clearly reduced by encapsulating the drug in liposomes.
Rat PK After bolus intravenous administration of UCN-01 solution, the drug was eliminated rapidly from blood (Fig.  5) ; the blood level of total UCN-01 was 1.2% of the injected dose at 5 min after injection and 0.02% at 24 h. The pharmacokinetic data (Table 1) were similar to those reported previously. 7, 8) After intravenous administration of UCN-01 liposomes, the blood level of total UCN-01 (i.e. the sum of the concentrations of drug in liposomes and bound to protein, as well as free drug) was much higher than that after administration of UCN-01 solution; the blood level of total UCN-01 was 66.2% of the injected dose at 5 min after injection and 2.4% at 24 h. The AUC 0-∞ of total UCN-01 after injection of UCN-01 liposomes was 127 times that after injection of UCN-01 solution. The V dss of administration of the liposomal formulation of the drug relative to the that after administration of drug solution; the V dss after injection of liposomes approximated to the blood volume suggesting that the majority of the drug is retained in the blood compartment. The CL tot of total UCN-01 was also much lower after injection of UCN-01 liposomes, presumably because the drug was not exposed to elimination processes. The combination of a smaller volume of distribution and lower clearance after administration of the liposomal preparation of UCN-01 conspired to produce an elimination half-life that was similar to that obtained after administration of the solution (see Table  1 ). Generally, encapsulation of drugs into liposomes prolongs the half-life of drugs. 14) Coadministration of UCN-01 solution with hAGP to rats significantly increased the total UCN-01 blood level (see Fig.  6 ), as described previously. 7, 8) The AUC 0-∞ of total UCN-01 after injection of UCN-01 with hAGP was 275 times that after injection of UCN-01 solution alone (Table 1) . On the other hand, the high blood level of total UCN-01 after administration of UCN-01 liposomes was not so markedly affected by the presence of hAGP; the AUC 0-∞ of UCN-01 after injection of UCN-01 liposomes with hAGP was 2.5 times that after injection of UCN-01 liposomes alone (Table 1) .
In Vivo hAGP Binding Experiments As described Table 1 . Pharmacokinetic Parameters of UCN-01 and UCN-01 Liposomes above, the blood levels of total UCN-01 were similar after intravenous administration to rats of UCN-01 solution with hAGP and UCN-01 liposomes with hAGP (Fig. 6) . However, measurement of total UCN-01 did not reveal whether UCN-01 was retained in liposomes and how much drug was bound to hAGP. In order to clarify the distribution of the drug in blood, aliquots of blood samples were subjected to Sepharose CL-6B gel chromatography as described in Materials and Methods. When UCN-01 solution was administered with hAGP, all the UCN-01 in blood bound to hAGP at all time points (see Fig. 7 ). On the other hand, when UCN-01 liposomes were administered with hAGP, part of the UCN-01 was retained in liposomes. The proportion of UCN-01 in liposomes gradually decreased with time; 5 min, 6 h and 24 h after injection of UCN-01 liposomes plus hAGP to rats, 63.9%, 17.9% and 1.4%, respectively, of the UCN-01 was retained within liposomes in the blood (Fig. 7) . No free UCN-01 was detected; all the UCN-01 released from liposomes that remained in the blood was bound to hAGP. DISCUSSION UCN-01, which inhibits protein kinases, exhibits potent anticancer activity in vitro and in vivo. 4, 5) However, safe and effective clinical use of the compound may be somewhat compromised by specific, high affinity binding of the compound to hAGP. [7] [8] [9] This binding to hAGP may prevent UCN-01 being delivered to the cytoplasm of the tumor and interacting with the target molecules, because, when plasma concentrations of UCN-01 are less than those of hAGP, all the administered UCN-01 would be present in the hAGPbound form thereby effectively "trapping" the drug in the plasma compartment. 8) Free UCN-01 would appear in blood only when the plasma concentrations of UCN-01 are above the hAGP levels. Consequently, administration of high doses of UCN-01 to patients would be required to provide free UCN-01 in plasma and to exhibit antitumor activity. However, potentially large intra-patient and inter-patient variation in AGP levels may mean that after administration of high doses of UCN-01, some patients could be exposed to high concentrations of free UCN-01 in blood and be at risk from severe side effects.
10) Dose escalation protocols and/or therapeutic monitoring of UCN-01 and measurement of hAGP may enable safe and effective clinical use of the drug. However, approaches that could negate the effect of high affinity binding of UCN-01 to hAGP would be attractive. Encapsulation of UCN-01 in liposomes was proposed as a possible method of avoiding the therapeutic impact of the high affinity binding of UCN-01 to hAGP. In the present study, UCN-01 was efficiently incorporated into liposomes in response to a pH gradient by methods similar to those previously described for preparing doxorubicin liposomes. 20) The release of UCN-01 from these liposomes both in vitro and in vivo was examined.
An important consideration in the development of a liposomal formulation is how to avoid rapid release of the drug from liposomes in blood. If drug is released too rapidly from liposomes the formulation is unlikely to offer advantages. Charrois et al. demonstrated that liposomes that release drug slowly have a better therapeutic activity than liposomes that release drug rapidly.
23) The rate of release from liposomes is drug dependent. Doxorubicin is only slowly released from liposomes. 14) On the other hand, ciprofloxacin and vincristine leak out of liposomes rapidly. 24) The data produced in the present study indicate that UCN-01 belongs to the group of drugs that are released from liposomes relatively quickly when the liposomes are added to blood (see Fig. 3 ).
The release of drugs from liposomes in blood is generally caused by serum proteins such as high density lipoproteins (HDL). 25, 26) HDLs remove phospholipid molecules from the vesicle bilayer thereby causing gaps to appear through which the drug can pass. Soluble proteins, such as albumin and AGP, usually do not induce the release of drugs from liposomes. However, rapid release of UCN-01 from liposomes occurred in the presence of hAGP (Fig. 3) . hAGP binds UCN-01 with high affinity, whereas rat AGP only nonspecifically binds UCN-01. 7) Thus, the increased leakage of UCN-01 from liposomes in the presence of hAGP might be explained by the specific binding of the drug to hAGP. It is hypothesized that UCN-01 is released efficiently from liposomes in the presence of hAGP because ideal sink conditions exist on the outside of the liposome due to the high affinity binding of drug to hAGP. The release of UCN-01 from liposomes in rat plasma supplemented with hAGP is likely to be a good representation of the release of drug in human blood in vivo.
Although UCN-01 was released from liposomes relatively efficiently in the presence of hAGP, a portion of the drug remained encapsulated for up to 24 h so that the proportion of total UCN-01 in blood that was bound to hAGP was clearly lower when the drug was added in liposomes as compared with UCN-01 solution. Coadministration of UCN-01 and hAGP to rats has been used to mimic the situation in human [7] [8] [9] ; in the present study, encapsulating UCN-01 into liposomes was effective in preventing UCN-01 binding to hAGP in vivo as well as in vitro. After injection of UCN-01 solution together with hAGP, all the UCN-01 was bound to hAGP at every time point. On the other hand, when UCN-01 liposomes were administered with hAGP, 17.9% of the injected UCN-01 remained in liposomes 6 h after injection (Fig. 7) . Using liposome encapsulated doxorubicin, Vaage et al. demonstrated that a proportion of the liposomes had already accumulated in the tumor at 6 h after intravenous injection. 27 ) Therefore, we conclude that UCN-01 liposomes would deliver more unbound drug to tumors than UCN-01 solution.
It remains an unsettled question whether UCN-01 accumu- lated in tumor tissue could transfer from liposomes into cytoplasm of the tumor without binding to hAGP. It is not to be denied that a large amount of hAGP exists around tumors. 28) The binding of UCN-01 with the hAGP around tumors could decrease the efficacy. The decrease of the efficacy could depend on the pathology. However, it is likely that the stacking of liposomes onto tumors prevents contacting of UCN-01 to hAGP and UCN-01 transfers directly from liposomes into cytoplasm of the tumor without binding to hAGP. From now on, the efficacy study in vivo will be needed to clarify both whether UCN-01 liposomes exhibit anticancer activity in the presence of hAGP and whether variations in hAGP levels have any effect on the efficacy.
A further question which needed to be asked is how to retain more UCN-01 in liposomes for longer and eliminate the effect of hAGP levels in blood on the release of UCN-01 from liposomes in order to optimize the clinical antitumor efficacy and safety profile of the drug. Many methods for improving retention of drugs in liposomes have been reported. For example, the addition of cholesterol is a well-known method 25) and Maurer-Spurej et al. improved the retention of ciprofloxacin and vincristine by substitution of the anionic lipid distearoylphosphatidyl-glycerol for distearoylphosphatidylcholine in the large unilamellar vesicle bilayer.
24) The retention of UCN-01 in liposomes might be improved by this method. The improving retention of UCN-01 in liposomes could eliminate the effect of hAGP levels in blood on the release at the same time.
In summary, the present study demonstrated that encapsulation of UCN-01 into liposomes was an effective method of protecting the drug from binding to hAGP. Therefore, it is feasible that more drug can be delivered to the site of action, tumors, by administering the drug in liposomes rather than as a solution. It is hoped that a liposomal formulation of UCN-01 will offer an improved clinical effectiveness and safety profile.
